Stock price of Geron Corporation (NASDAQ:GERN) has been quite unstable during the past days. After a week full of losses, on 
Friday the stock soared 2.76% and its traded volume jumped over 2 million shares. Though, the reason for the massive trade is yet unknown.
Historical data shows that there is not much news about Geron these days, so no one has a clue about its operations. The last news by the company was released on Dec 12, when GERN reported the initiation of Phase 2 trial of GRN1005 in brain metastases from breast cancer.
The company’s team has been encouraged by the preliminary evidence of anti-tumor activity observed in the Phase 1 clinical trial of GRN1005 and they hope to confirm these results in the Phase 2 study. Though, it is still to be seen.
Apart from this announcement, no other news on GERN has been released lately besides a few promotional publications on the company. However, these failed to influence the stock price and its next step looks unpredictable.
Geron Corporation operates as a biopharmaceutical company in the US. Lately, there’s been strong activity with Geron’s shares of common stock, however, its financial results are not satisfying enough.[BANNER]
According to the company’s last quarterly report, the results of operations have fluctuated from period-to-period and may continue to fluctuate in the future. In addition, Geron is subject to risks common to companies in its industry, including risks related to its research and development efforts, need for future capital, timely completion of its clinical trials, etc.
GERN still has cash on hand to perform operations, however, it does not expect to receive revenues or royalties based on therapeutic products for a period of years, if at all.
